New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial

NCT ID NCT07660055

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 4 times

Summary

This early-stage trial is testing a new type of radiation therapy that seeks out and attacks cancer cells while sparing healthy tissue. It's for people with advanced breast, lung, stomach, or bladder cancer who have run out of standard options. The study will check if the treatment is safe, what dose works best, and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: radioligand therapy (177Lu-DWJ155) and imaging agent (68Ga-DWJ155)
What this could lead to: If successful, this could lead to a new targeted treatment option for several hard-to-treat solid tumors.
What could go wrong: This is an early Phase 1 trial, so safety and dosing are still being figured out. It may not shrink tumors or work for all cancer types tested.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm gastric cancer gastroesophageal cancer gastroesophageal junction adenocarcinoma HER2 positive breast carcinoma hormone receptor-positive breast cancer neoplasm non-small cell lung carcinoma triple-negative breast carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER BREAST CANCER GASTRIC/GASTROESOPHAGEAL JUNCTION (GEJ) CANCER NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Nebraska Cancer Specialists
RECRUITING

Omaha, Nebraska, 68130, United States
Novartis Investigative Site
RECRUITING

Darlinghurst, New South Wales, 2010, Australia
Novartis Investigative Site
RECRUITING

Montreal, Quebec, H4A 3J1, Canada
Novartis Investigative Site
RECRUITING

Kashiwa, Chiba, 277-8577, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.